Back to top
more

SiBone (SIBN)

(Delayed Data from NSDQ)

$13.49 USD

13.49
249,126

-0.31 (-2.25%)

Updated Nov 1, 2024 03:59 PM ET

After-Market: $13.48 -0.01 (-0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 250)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Abbott (ABT) to Advance Diabetes Care With New Acquisition

by Zacks Equity Research

Abbott's (ABT) recent deal will enable it to create more interconnected solutions to improve the personalization and accuracy of diabetes control.

Here's Why You Should Retain Omnicell (OMCL) Stock Now

by Zacks Equity Research

Investors are optimistic about Omnicell (OMCL), owing to the strong prospect of the advanced services portfolio.

Does Si-Bone (SIBN) Have the Potential to Rally 39.93% as Wall Street Analysts Expect?

by Zacks Equity Research

The consensus price target hints at a 39.9% upside potential for Si-Bone (SIBN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Why You Should Add Haemonetics (HAE) to Your Portfolio Now

by Zacks Equity Research

Haemonetics' (HAE) share price is likely to grow, backed by solid business performance across all its segments.

Charles River (CRL) Gains From Global Demand Amid FX Woes

by Zacks Equity Research

Charles River (CRL) broadens the scope of the products and services across the drug discovery and early-stage development continuum through focused acquisitions.

Here's Why You Should Retain Boston Scientific (BSX) Now

by Zacks Equity Research

Investors are optimistic about Boston Scientific (BSX) on growth in the legacy business and upbeat guidance.

Zimmer Biomet (ZBH) Business Recovery Continues Despite FX Woe

by Zacks Equity Research

Zimmer Biomet (ZBH) is benefiting from increased provider capacity, resulting in backlog pull-through in the recent quarters.

LivaNova (LIVN) Advances Cardiopulmonary Wing With Essenz ILBM

by Zacks Equity Research

LivaNova's (LIVN) Essenz ILBM boasts B-Capta sensing technology, ensuring accuracy and compliance with Clinical Laboratory Improvement Amendments.

Here's Why You Should Retain Teleflex (TFX) Stock for Now

by Zacks Equity Research

A diversified product portfolio and a broad geographic footprint bode well for Teleflex (TFX).

Globus Medical (GMED) Completes NuVasive Merger Agreement

by Zacks Equity Research

Globus Medical's (GMED) recent deal combines complementary spine and orthopedic solutions, enabling technologies to create one of the industry's most comprehensive, innovative offerings.

ICU Medical's (ICUI) Plum Duo With Safety Shield Gets 510(k) Nod

by Zacks Equity Research

The Plum Duo infusion pump represents the latest addition to ICU Medical's (ICUI) advanced lineup of infusion devices.

Neogen (NEOG) Launches SureKill Evolve SC Pest Management Tool

by Zacks Equity Research

Neogen (NEOG) introduces the latest solution in the SureKill brand of products, SureKill Evolve SC.

Boston Scientific's (BSX) FARAPULSE System Study Data Positive

by Zacks Equity Research

Boston Scientific's (BSX) FARAPULSE PFA System's performance in the trial is an encouraging sign of the potential utilization of the device in the United States.

Walgreens (WBA) OTC NARCAN Nasal Spray to be Available Soon

by Zacks Equity Research

Walgreens (WBA) is instructing Americans to administer this life-saving drug that, if given in time, can reverse the effects of an opioid overdose.

Abbott's (ABT) Libre Gains Momentum Amid Low Testing Sales

by Zacks Equity Research

Banking on the successful execution of Abbott's (ABT) branded generic operating model, EPD is well positioned for sustained growth in many of the growing pharmaceutical markets.

Inspira (IINN) Advances Foothold in Europe With Extended Deal

by Zacks Equity Research

The extended service agreement complements a previously announced strategic agreement between Inspira (IINN) and Innovimed.

Here's Why You Should Retain Integra (IART) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Integra (IART) based on the prospects of its CSS segment and a stable liquidity position.

Exact Sciences' (EXAS) OncoExtra Test Selected for ComboMATCH

by Zacks Equity Research

Exact Sciences' (EXAS) Laboratory and OncoExtra test gets selected by the NCI for ComboMATCH trials.

Here's Why You Should Invest in Neogen (NEOG) Stock Now

by Zacks Equity Research

Investors are optimistic about Neogen (NEOG) on recent product launches.

STERIS (STE) Banks on New Pact for Growth Amid Rising Expenses

by Zacks Equity Research

Continuous procedure volume growth in the United States, favorable pricing and market share gains are driving STERIS' (STE) Healthcare segment organic growth.

Haemonetics (HAE) Expands VASCADE System Portfolio in Germany

by Zacks Equity Research

Haemonetics (HAE) announces the first treatment of patients in Germany with the VASCADE MVP Venous Vascular Closure system.

Here's Why You Should Retain Zimmer Biomet (ZBH) for Now

by Zacks Equity Research

Investors are optimistic about Zimmer Biomet (ZBH) due to innovative new product launches and solid execution.

Insulet (PODD) Launches Omnipod 5 AID System in Germany

by Zacks Equity Research

Insulet's (PODD) Omnipod 5 is available in the United States and the United Kingdom.

Here's Why You Should Retain Henry Schein (HSIC) Stock for Now

by Zacks Equity Research

Investors are optimistic about Henry Schein (HSIC), led by the strength of its dental business.

Orthofix's (OFIX) New Launch to Benefit the MIS Spine Market

by Zacks Equity Research

Orthofix (OFIX) announces the commercial launch and the successful completion of the first cases in the United States with the 7D FLASH Navigation System Percutaneous Module 2.0.